Even a mild anemia is related to tumor aggressiveness mediated by angiogenic factors

Experimental Oncology

Volumn 31, Issue 1, 2009, Pages 52-56

  Krzystek Korpacka, M ^a   Matusiewicz, M ^a   Diakowska, D ^a   Grabowski, K ^a   Blachut, K ^b   Kustrzeba Wojcicka, I ^a   Gamian, A ^a,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Department of Gastroenterology and Hepatology   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Anemia; Angiogenesis; Esophagogastric cancer; Metastasis

Indexed keywords

ANGIOGENIC FACTOR; HEMOGLOBIN; INTERLEUKIN 8; MIDKINE; VASCULOTROPIN A; VASCULOTROPIN C; CYTOKINE; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ANEMIA; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ESOPHAGUS CANCER; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METASTASIS; STOMACH CANCER; ADULT; AGED; BLOOD; ESOPHAGUS TUMOR; IMMUNOLOGY; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANGIOGENESIS INDUCING AGENTS; CYTOKINES; ESOPHAGEAL NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; INTERLEUKIN-8; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 65549151295     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Blohmer J.-U. Dunst J. Harrison L. Johnston P. Khayat D. Ludwig H. O'Brien M. Van Belle S. Vaupel P. Cancer-related anemia: Biological findings, clinical implications and impact on quality of life Oncology 2005 68 SUPPL. 1 12-21 DOI 10.1159/000083129 1. Blohmer J-U, Dunst J, Harrison L, et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005; 68 (Suppl 1): 12-21. (Pubitemid 40663256)
2. Park SH, Lee J, Lee SH, et al. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2006; 57: 91-96
3. Alici S, Kaya S, Izmirli M, et al. Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 2006; 12: CR221-9.
4. Kuo LJ, Leu SY, Liu MC, et al. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum 2003; 46: 1646-1652
5. van Halteren H.K. Houterman S. Verheij C.D.G.W. Lemmens V.E.P.P. Coebergh J.W.W. Anaemia prior to operation is related with poorer long-term survival in patients with operable rectal cancer European Journal of Surgical Oncology 2004 30 6 628-632 DOI 10.1016/j.ejso.2004.04.014, PII S074879830400112X 5. van Halteren HK, Houterman S, Verheij CD, et al. Anaemia prior to operation is related with poorer long-term survival in patients with operable rectal cancer. Eur J Surg Oncol 2004; 30: 628-632 (Pubitemid 39060732)
6. Yovino S. Kwok Y. Krasna M. Bangalore M. Suntharalingam M. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone International Journal of Radiation Oncology Biology Physics 2005 62 5 1438-1443 DOI 10.1016/j.ijrobp.2004.12.038, PII S0360301604031566 6. Yovino S, Kwok Y, Krasna M, et al. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 2005; 62: 1438-1443 (Pubitemid 40982067)
7. Blackwell K. Gascon P. Sigounas G. Jolliffe L. rHuEPO and improved treatment outcomes: Potential modes of action Oncologist 2004 9 SUPPL. 5 41-47 DOI 10.1634/theoncologist.9-90005-41 7. Blackwell K, Gascon P, Sigounas G, Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004; 9: 41-47 (Pubitemid 39658344)
8. Dunst J. Kuhnt T. Strauss H.G. Krause U. Pelz T. Koelbl H. Haensgen G. Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis International Journal of Radiation Oncology Biology Physics 2003 56 3 778-787 DOI 10.1016/S0360-3016(03)00123-8 8. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiotion Oncology Biol Phys 2003; 56: 778-787 (Pubitemid 36677372)
9. Varlotto J. Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient International Journal of Radiation Oncology Biology Physics 2005 63 1 25-36 DOI 10.1016/j.ijrobp.2005.04.049 9. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005; 63: 25-36. (Pubitemid 41583539)
10. Dunst J. Stadler P. Becker A. Kuhnt T. Lautenschlager C. Molls M. Haensgen G. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers Strahlentherapie und Onkologie 2001 177 9 469-473 10. Dunst J, Stadler P, Becker A, et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2001; 177: 469-473 (Pubitemid 32861427)
11. Koukourakis M.I. Giatromanolaki A. Sivridis E. Pastorek J. Karapantzos I. Gatter K.C. Harris A.L. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer International Journal of Radiation Oncology Biology Physics 2004 59 1 67-71 DOI 10.1016/j.ijrobp.2003. 10.016, PII S0360301603022119 11. Koukourakis ML, Giatromanolaki A, Sivridis E, et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiotion Oncology Biol Phys 2004; 59: 67-71. (Pubitemid 38501508)
12. Porta C, Imarisio I, De Amici M, et al. Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncol Rep 2005; 13: 689-695
13. Rades D. Lang S. Schild S.E. Alberti W. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer Clinical Oncology 2006 18 2 139-144 DOI 10.1016/j.clon.2005.10.007, PII S0936655505004309 13. Rades D, Lang S, Schild SE, Alberti W. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol 2006; 18: 139-144 (Pubitemid 43169143)
14. Rades D. Schild S.E. Bahrehmand R. Zschenker O. Alberti W.A. Rudat V.R. Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: The importance of pretreatment hemoglobin levels Cancer 2005 103 8 1740-1746 DOI 10.1002/cncr.20952 14. Rades D, Schild SE, Bahrehmand R, et al. Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer 2005; 103: 1740-1746 (Pubitemid 40490037)
15. Rades D, Schild SE, Yekebas EF, et al. Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. Cancer 2005; 103: 2274-2279
16. Rades D, Tribius S, Yekebas EF, et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 2006; 65: 459-465
17. Beecken W.-D. Kramer W. Jonas D. New molecular mediators in tumor angiogenesis Journal of Cellular and Molecular Medicine 2000 4 4 262-269 17. Beecken WD, Kramer W, Jonas D. New molecular mediators in tumor angiogenesis. J Cell Mol Med 2000; 4: 262-269 (Pubitemid 33223560)
18. Krzystek-Korpacka M. Matusiewicz M. Diakowska D. Grabowski K. Blachut K. Banas T. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC) Cancer Letters 2007 249 2 171-177 DOI 10.1016/j.canlet.2006.08.011, PII S0304383506005052 18. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 2007; 249: 171-177 (Pubitemid 46452923)
19. Krzystek-Korpacka M. Matusiewicz M. Diakowska D. Grabowski K. Blachut K. Kustrzeba-Wojcicka I. Banas T. Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in oesophageal squamous cell carcinoma Biomarkers 2007 12 4 403-413 DOI 10.1080/13547500701192470, PII 779501170 19. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in esophageal squamous cell carcinoma. Biomarkers 2007; 12: 403-413. (Pubitemid 46952301)
20. Lee K.H. Bae S.H. Lee J.L. Hyun M.S. Kim S.H. Song S.K. Kim H.S. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer Oncology 2004 66 3 210-217 DOI 10.1159/000077997 20. Lee KH, Bae SH, Lee JL, et al. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology 2004; 66: 210-217 (Pubitemid 38813048)
21. Shimada H. Takeda A. Nabeya Y. Okazumi S.-I. Matsubara H. Funami Y. Hayashi H. Gunji Y. Kobayashi S. Suzuki T. Ochiai T. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma Cancer 2001 92 3 663-669 DOI 10.1002/1097-0142(20010801)92:3<663::AID- CNCR1368>3.0.CO;2-L 21. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-669 (Pubitemid 32735204)
22. Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th edn. New Jersey: John Wiley & Sons, Hoeboken, 2002.
23. Krzystek-Korpacka M. Matusiewicz M. Grabowski K. Diakowska D. Boehm D. Kustrzeba-Wojcicka I. Banas T. Immunoenzymatic method for midkine determination in serum Advances in Clinical and Experimental Medicine 2006 15 2 247-252 23. Krzystek-Korpacka M, Matusiewicz M, Grabowski K, et al. Immunoenzymatic method for midkine determination in serum. Adv Clin Exp Med 2006; 15: 247-252 (Pubitemid 43833941)
24. Knight K. Wade S. Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature American Journal of Medicine 2004 116 7 SUPPL. 1 11-26 DOI 10.1016/j.amjmed.2003.12.008, PII S0002934303007708 24. Knight K, Wady S, Balducci L. Prevalence and outcomes of anemia in cancer: a systemic review of the literature. Am J Med 2004; 116: 11S-26S. (Pubitemid 38429897)
25. Fyles A.W. Milosevic M. Pintilie M. Syed A. Hill R.P. Anemia, hypoxia and transfusion in patients with cervix cancer: A review Radiotherapy and Oncology 2000 57 1 13-19 DOI 10.1016/S0167-8140(00)00245-0, PII S0167814000002450 25. Fyles AW, Milosevic M, Pintilie M, et al. Anemia, hypoxia and transfusion in patients with cervical cancer: a review. Radiother Oncol 2000; 57: 13-19 (Pubitemid 30738398)
26. Valencia Julve J, Alonso Orduna V, Esco Baron R, et al. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 2006; 8: 22-30.
27. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306
28. Achen MG, Stacker SA. Tumor lymphangiogenesis and metastatic spread-New players begin to emerge. Int J Cancer 2006; 119: 1755-1760
29. Krzystek-Korpacka M. Matusiewicz M. Diakowska D. Grabowski K. Blachut K. Kustrzeba-Wojcicka I. Banas T. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-α, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients Clinical Biochemistry 2007 40 18 1353-1360 DOI 10.1016/j.clinbiochem. 2007.07.013, PII S0009912007002986 29. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-α, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Bioch 2007; 40: 1353-1360 (Pubitemid 350151421)
30. Maccio A. Madeddu C. Massa D. Mudu M.C. Lusso M.R. Gramignano G. Serpe R. Melis G.B. Mantovani G. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia Blood 2005 106 1 362-367 DOI 10.1182/blood-2005-01-0160 30. Maccio A, Madeddu C, Massa D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005; 106: 362-367 (Pubitemid 40967214)
31. Dunst J. Becker A. Lautenschlager C. Markau S. Becker H. Fischer K. Haensgen G. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF) Strahlentherapie und Onkologie 2002 178 8 436-441 DOI 10.1007/s00066-002-0925-8 31. Dunst J, Becker A, Lautenschlager C, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002; 178: 436-441 (Pubitemid 34847423)
32. Dunst J, Pigorsch S, Hansgen G, et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol 1999; 175: 93-96
33. Birgegard G. Aapro M.S. Bokemeyer C. Dicato M. Drings P. Hornedo J. Krzakowski M. Ludwig H. Pecorelli S. Schmoll H. Schneider M. Schrijvers D. Shasha D. Van Belle S. Cancer-related anemia: Pathogenesis, prevalence and treatment Oncology 2005 68 SUPPL. 1 3-11 DOI 10.1159/000083128 33. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68: 3-11. (Pubitemid 40663255)
34. Haugen H. Magnusson B. Svensson M. Mercke C. Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy Clinical Cancer Research 2004 10 23 7941-7949 DOI 10.1158/1078-0432.CCR-04-0871 34. Haugen H, Magnusson B, Svensson M, Mercke C. Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radiotherapy. Clin Cancer Res 2004; 10: 7941-7949 (Pubitemid 39587534)
35. Vaupel P. Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response Oncologist 2004 9 SUPPL. 5 4-9 35. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9: 4-9. (Pubitemid 39658340)
36. Marjon PL, Bobrovnikova-Marjon EV, Abcouwer SF. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Mol Cancer 2004; 3: 4
37. Aoe K. Hiraki A. Maeda T. Katayama H. Fujiwara K. Tabata M. Kiura K. Ueoka H. Tanimoto M. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer Internal Medicine 2005 44 8 800-804 DOI 10.2169/internalmedicine.44.800 37. Aoe K, Hiraki A, Maeda T, et al. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. Internal Medicine 2005; 44: 800-804 (Pubitemid 41263823)